Ascendiant raised the firm’s price target on Lucid Diagnostics (LUCD) to $7.75 from $7.50 and keeps a Buy rating on the shares following the Q1 report. The firm says expected high growth in 2025 should drive the stock “much higher.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics Enters $25M Sales Agreement
- Lucid Diagnostics to join Russell 2000, Russell 3000 indexes
- Lucid Diagnostics director buys $457.6K in common stock
- Lucid Diagnostics files to sell 36.98M shares of common stock for holders
- Lucid Diagnostics Reports Increased Losses Amid Revenue Decline